Associations - EGFR inhibitor

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR expression	Lung Non-Small Cell Squamous Cancer	EGFR expression	Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1
HER-2 overexpression	Hormone Receptor Negative Breast Cancer	HER-2 overexpression	Hormone Receptor Negative Breast Cancer	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1	trastuzumab + lapatinib Sensitive: A1 - Approval trastuzumab + lapatinib Sensitive : A1
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1	lapatinib Sensitive: A1 - Approval lapatinib Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A146	Colorectal Cancer	KRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1

EGFR inhibitor

EGFR inhibitor

Associations(2234)

Associations
(2234)